AlzeCure Pharma AB Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) announced that an abstract with preclinical data on NeuroRestore ACD856 demonstrating its anti-inflammatory and immunomodulatory effects has been accepted for presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in Madrid, Spain, on October 29 - November 1.

The abstract, titled Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer's disease, will be presented at the conference by Dr. Cristina Parrado-Fernández, Senior Scientist at AlzeCure.  The presentation includes new preclinical results with ACD856, the lead clinical drug candidate within the NeuroRestore platform.

The data show that the substance shows both anti-inflammatory and immunomodulating properties, something that has been demonstrated after treatment in both aged animals and in Alzheimer's models. This indicates potentially disease-modifying properties of this class of molecules. Previous preclinical studies have shown that AlzeCure's drug candidates in the NeuroRestore platform strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions.

Preclinical results from AlzeCure also show neuroprotective, anti-inflammatory and disease-modifying effects in various models with these so-called Trk-PAM substances. The unique pharmacological mechanism of NeuroRestore also enables several indications, such as Alzheimer's and Parkinson's disease, but also depression. ACD856 is a first-in-class drug candidate for Alzheimer's disease and is now being prepared for upcoming phase II clinical studies in patients.